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Abstract: Potent antibody-mediated neutralization is critical for an organism to combat the vast
array of pathogens it will face during its lifetime. Due to the potential genetic diversity of some
viruses, such as HIV-1 and influenza, standard neutralizing antibodies are often ineffective or easily
evaded as their targets are masked or rapidly mutated. This has thwarted efforts to both prevent
and treat HIV-1 infections and means that entirely new formulations are required to vaccinate
against influenza each year. However, some rare antibodies isolated from infected individuals confer
broad and potent neutralization. A subset of these broadly neutralizing antibodies possesses a long
complementarity-determining 3 region of the immunoglobulin heavy chain (CDR H3). This feature
generates unique antigen binding site configurations that can engage conserved but otherwise
inaccessible epitope targets thus neutralizing many viral variants. Remarkably, ultralong CDR H3s
are a common feature of the cow antibody repertoire and are encoded by a single variable, diversity,
joining (VDJ) recombination that is extensively diversified prior to antigen exposure. Recently, it was
shown that cows rapidly generate a broadly neutralizing response upon exposure to HIV-1 and this is
primarily mediated by these novel ultralong antibody types. This review summarises the current
knowledge of these unusual CDR H3 structures and discusses their known and potential future uses.
Keywords: broadly neutralizing antibodies; ultralong CDR H3; bovine antibodies; antibody diversity
1. Introduction
Jawed vertebrates generate millions of B cells every day, each of which expresses a unique
antigen receptor, either on the cell surface as a B-cell receptor (BCR) or secreted in the form of an
antibody (Ab). These receptors consist of two identical light chains and two identical heavy chains
joined by non-covalent interactions and disulphide bonds. Each individual polypeptide chain has
an N-terminal variable domain and a C-terminal constant domain, where the constant domain of the
heavy chain determines the Ab isotype (IgM, IgD, IgG, IgA or IgE). The variable domain is unique to
each BCR and it is this region that contacts the antigen, determining the Ab specificity [1]. The variable
domains of the heavy and the light chains each contains four framework regions (FRs) and three
complementarity-determining regions (CDRs). The FRs are associated with structural stability and act
as a scaffold for the Ab structure, whereas the CDRs are hyper-mutable and form the antigen binding
site (paratope) that interacts with a specific region of the antigen (epitope). The CDR 3 of the heavy
chain (CDR H3) typically forms a large fraction of the antigen binding pocket [2,3].
Antibody diversity is fundamental to eliminating the array of pathogens that the host could
encounter. The assembly of the pre-immune Ab repertoire begins in pro-B cells within the bone marrow
when one from each of the variable (V), diversity (D) and joining (J) gene segments is assembled
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into a contiguous variable exon at the heavy chain locus (IgH) by V(D)J recombination. This process
is catalysed by the lymphoid-specific recombination activating gene (RAG) 1 and RAG 2 proteins
(Figure 1). RAG-mediated cleavage is targeted to the V, D and J gene segments by recombination
signal sequences (RSSs) that consist of a conserved heptamer and nonamer, separated by a relatively
non-conserved spacer of 12± 1 or 23± 1 base pairs. Following cleavage, the broken ends are shepherded
towards the canonical non-homologous end-joining repair pathway for processing and ligation [4–6].
Primary diversity is focussed in the sequence encoding the CDR H3 loop and sequence diversity here
is increased by non-templated nucleotide additions and exonucleolytic trimming [7,8]. The generation
of the variable exon at the light chain loci is analogous, except recombination is between V and J gene
segments only.
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Figure 1. Assembly of Immunoglobulin Genes by V(D)J recombination. V(D)J recombination is
a step-wise process that produces a contiguous variable exon from distinct germline segments.
The complementarity determining region 3 of the heavy chain is encoded by the 3′ sequence of the V
gene segment, the entire D gene segment and sequences at the 5′ end of the J segment. The framework
and complementarity-determining regions are labelled, while the conserved features that demarcate
the immunoglobulin heavy chain CDR H3 are indicated. The gaps between gene segments, shaded
light grey, represent N-nucleotides. RAG1 and RAG2 proteins are depicted as a dark grey oval; proteins
involved in end joining, Ku70/Ku80 heterodimer, Artemis, DNA protein kinase catalytic subunit
(DNA-PKcs), Terminal deoxynucleotide transferase (TdT), X-ray repair cross complementing protein 4
(XRCC4) and DNA ligase IV, are indicated. A functional B-cell receptor is generated following light
chain recombination and the subsequent pairing of the heavy (VH) and light (VL) chains. In some cases,
V(D)J recombination can generate long CDR H3 loops that form unusual paratope structures.
Exposure to antigen in the germinal centres (GC) of the secondary lymphoid tissues induces the
marked diversification of the Ab sequences. This tightly regulated process of somatic hypermutation
(SHM) is initiated by activation-induced cytosine deaminase (AID) activity and the recruitment of
downstream repair enzymes that are uniquely error-prone at the immunoglobulin loci [9]. Assuming
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it is functional, the newly mutated Ab, with a novel binding site, is then tested for improved antigen
binding affinity as the B cell migrates to the light zone of the GC. The ability of B cells to discriminate
the affinity of their unique receptor for an antigen efficiently ensures that advantageous mutations
are favoured, with a concomitant improvement in antigen binding [10,11]. Owing to their limited
number of Ig gene segments, cows (Bos taurus) depend upon this AID-induced SHM to expand their
limited pre-immune Ab repertoire prior to antigen exposure [12]. Jointly, these Ab diversification
mechanisms generate a vast Ab repertoire. Some viruses, including HIV-1, influenza and Ebola, utilise
a multitude of evasive tools to circumvent the host immune system. Some of these pathogens have an
enormous variety of globally circulating strains, can rapidly diversify their surface antigens, or occlude
epitopes that are evolutionary conserved, to limit their immunogenicity. Such strategies severely
limit the effectiveness of typical neutralizing Ab responses [13]. However, it was observed that the
Abs from some chronically HIV-1 infected patients exhibit broad and potent neutralization of many
viral variants [14]. Improved single-cell isolation, enhanced cloning techniques and the advent of
Next Generation Sequencing (NGS) have since facilitated the isolation, generation and subsequent
characterization of many of these broadly neutralizing Abs (BNAbs) [15,16]. Notably, one of the most
striking features of some BNAbs is a long (≥20 amino acids) CDR H3 [17]. Recently, it has been shown
that Abs with ultralong CDR H3s make up a significant fraction of cow Abs [18,19] and an effective
BNAb response can be rapidly generated in cows in as little as six weeks [20]. Similarly, the heavy
chain only ‘nanobodies’ generated by Camelidae utilise a long CDR H3 to bind to hidden epitopes that
can neutralize a broad cohort of HIV variants [21,22].
This review focuses on such BNAbs, and in particular on their extended CDR H3, a striking
feature that has been shown to facilitate the broad neutralization of HIV-1 and other viruses. While an
extended CDR H3 does not automatically confer neutralization properties per se, it does provide a
scaffold for unconventional paratope structures that can puncture viral defences, such as thick glycan
coats, to engage conserved epitope regions and thus neutralize many variants. We will summarise
the current knowledge of these unusual CDR H3 structures in humans and cows, whilst exploring
differences in the diversification mechanisms between these species, and discuss future strategies for
the utilisation of the novel properties of BNAbs.
2. The Long CDR H3 Is Generated Inefficiently in Humans
The most studied BNAbs are those from HIV-1 infected individuals. Although the mean CDR H3
length in human Abs is ≈15 amino acids [23], some anti-HIV-1 BNAb lineages have an extended CDR
H3 over 35 amino acids that is capable of reaching hidden epitopes typically associated with limited
Ab recognition [16]. The sequence encoding the CDR H3s of any Ab can be considered to begin after a
conserved cysteine codon (C104) at the 3′ end of FR3 in the V segment and extends to a conserved
W/F residue encoded at the 5′ end of the J segment that marks FR4 (Figure 1; IMGT numbering; [24]).
As such, it spans the entire D segment, two recombined junctions and is intrinsically variable. Indeed,
several lymphocyte-specific mechanisms have been described that can significantly extend the length
of the sequence encoding the CDR H3. The principal ways include extensive junctional diversity and
insertion/deletion mutations associated with SHM, but evidence has also been found for D-D gene
segment fusions and VH replacement events [17]. Though long CDR H3s are prevalent in the human
transitional and naïve B cell Ab repertoire, their frequency is reduced as B cells mature in normal
adult repertoires [25]. Indeed, Abs from memory B cells and plasmocytes exhibit a shorter mean
CDR H3, which likely indicates that long CDR H3s are not selected during affinity maturation [26].
It therefore seems that the generation of long CDR H3 BNAbs from the antigen-naïve repertoire in
humans is inefficient due to relatively few immunogens that target the germline-encoded BCRs, which
is compounded by the fact that the unmutated precursors of many mature BNAbs bind only weakly to
their relative antigen [27]. Indeed, broad and potent neutralization emerges stochastically in only some
individuals and only then after years of chronic infection. Invariably, this requires a co-evolutionary
process of sequential exposure to antigen variants together with iterative affinity maturation [15,16,28].
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It is notable that many individuals who do generate an effective broadly neutralizing response against
HIV-1 have Abs with a longer average CDR H3 [25].
When present, the long CDR H3 lifts the paratope away from the main antibody structure
and allows CDRs to adopt complex conformations that include long flexible loops with anionic
tips [28,29], high-affinity loop insertions [30] and intricately folded knob domains [18]. Most BNAbs
have undergone extensive SHM away from their germline configuration. This SHM frequently involves
insertion/deletion (indel) mutations of multiple codons [31], which often foster critical stabilizing
interactions between the protruding CDR H3 structure and the other CDRs in human BNAbs [16].
Moreover, as well as stabilizing the protruding structure and directly altering the antigen contacts, SHM
can generate local flexibility that allows the antigen-binding site to engage with its respective target at
a variety of angles, significantly improving neutralization activity in some cases [16]. Although rare in
human antibody genes, large nucleotide insertions (>40 nt) introduced by sequence duplication during
the error-prone repair of SHM have been shown to contribute to antigen recognition [32]. Whilst the
high SHM rate is not conducive to their induction via classical vaccination, it does not prevent the use
of previously generated BNAbs therapeutically [33,34].
Significant advances have been made regarding induction of HIV-1 BNAb precursors in transgenic
mice models carrying knock-ins of either the respective BNAbs germline V, D and J segments or
the near mature BNAb VDJ exon [35,36]. Further innovative efforts have enabled the use of these
novel extended CDR H3 Ab types for prophylaxis and therapy, and similar approaches have shown
considerable promise in clinical trials with HIV-1 infected individuals [34]. Expanding the search for
BNAbs into the Ab repertoires of diverse species will likely provide new opportunities to develop
immunotherapeutic agents.
3. Ultralong CDR H3 Are Prevalent in the Cow Ab Repertoire
In contrast to humans, the bovine immune system relies much more extensively on mechanisms
that occur after the original recombination event to diversify their immunoglobulin genes [37].
Only 12 IGHV, 16 IGHD and 4 IGHJ gene segments appear to be functional in cows [23], which is
significantly less than the >100 V, 25 D and 6 J gene segments found in humans. In cows, the initial lack
of diversity is compensated by extensive AID-induced SHM [37], which occurs in the gut-associated
lymphoid tissues prior to antigen exposure [12]. While diversification of the pre-immune Ab reservoir
has been shown to take place to some extent in the Peyer’s patch of mice [38], this is not a major driver
of primary Ab diversity as it is in the cow.
Cow antibodies can be split into two groups based on their CDR H3 lengths: 1–39 amino acids,
and 40–71 amino acids [18,39–41]. Recently, a detailed assembly of the bovine IgH locus was reported
(KT723008) [23] that localised all the functional IGH genes to chromosome 21 and also confirmed the
presence of a single, ultralong D segment (DH8-2) of 148 bp in length, although longer alleles have been
reported [12]. In comparison, the longest D segment in the human IgH locus is 37 bp (D3–16), while
mouse CDR H3s are typically even shorter than human CDR H3s; clearly, the potential for an ultralong
CDR H3 does not exist in the germline of these species [42,43]. Nonetheless, the NGS analysis of bovine
antibody repertoires [18] suggests that nearly all of the very long bovine Abs (40–71 amino acid CDR
H3) are generated by the diversification of just this one long D8-2 gene segment. In fact, these ultralong
CDR H3 sequences utilise the same V (VH1-7) and J (J2-4) gene segments in each case, together with
the long DH8-2. Structural studies have shown that the ultralong CDR H3s encode a long, solvent
exposed β−strand stalk that protrudes from the main Ab structure and supports a disulphide bonded
knob domain that is responsible for antigen binding [18]. Although it has also been reported that
insertion of up to 100 nucleotides at the VD or DJ junctions can generate very long CDR H3s from
shorter D gene segments in cows [23], it is not known if the resulting antigen receptors are functional.
Nonetheless, the bovine immune system is seemingly primed to elicit Abs with ultralong CDR H3s.
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4. Diversification of the Ultralong CDR H3 in Cows
AID activity plays a significant role in the generation of the bovine ultralong CDR H3 [37,44].
This SHM activity generates large internal deletions (≤50 nucleotides) and relatively large insertions
(≤20 nucleotides) within the DH8-2 segment, which diversify the pattern of disulphide bridge formation
to act as a rapid means of altering the antigen binding domain [37,44]. Though AID commonly
introduces point mutations and small insertion/deletion mutations in the Ig sequences of other
species, the deletions in bovine D8-2 are larger and more frequent than those observed in humans
or mice [37,38,44]. The overlapping AID targeting hotspots in the D8-2 segment may facilitate
the production of staggered double strand breaks (DSBs) by generating two single-strand nicks
simultaneously (Figure 2). This is analogous to the way in which AID generates DSBs in the Ig switch
regions [9,38] and in non-Ig genes, including the myc gene leading to the myc-IgH translocation [45].
The mechanisms mediating such large deletions and insertions in D8-2 are currently unknown but
may involve aspects of microhomology-mediated end-joining during direct DSB repair, or be the result
of template slippage events (Figure 2) [37] across the repetitive D8-2 sequence. Nonetheless, when
combined with extensive SHM, starting with a longer germline gene segment that is subsequently
trimmed internally is seemingly a very efficient method of producing a diverse antibody repertoire
from a single gene [37].
Further diversity in the bovine ultralong CDR H3 is contributed by the unusual, adenine-rich
insertions at the V-D junction that are likely deposited during the original V-DJ recombination
event [18,19]. These insertions are a significant difference from the TdT-mediated junctional diversity
that has been observed in human and mouse heavy chain rearrangements and the details of the bovine
insertion mechanism(s) remain unknown. However, due to its presence in the region encoding the
stem and its propensity for encoding hydrophilic residues [18], this non-germline sequence can likely
alter the orientation of the knob domain while maintaining the β−strand structure. This feature may
therefore change the local flexibility and geometry without compromising the overall stem stability [46].
Seven recent structures reveal that small changes (<7◦) in the angle of the stalk can lead to large changes
in the orientation of the putative antigen binding site [46]. Notably, a threonine is nearly always
found at the second position of this junctional insertion and is positioned directly opposite alternating
tyrosines (YxYxY) encoded in the germline and present in the descending side of the stem in the 3D
structure [18,47]. How changes specific to this V-D junctional sequence affect the binding or stability
of the structure has not yet been explored but could feasibly be examined via the alanine-scanning
mutagenesis of an Ab with a known antigen target of the ultralong CDR H3.
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Figure 2. A single recombined variable exon is diversified to generate the ultralong repertoire in cows.
(a) A schematic depicting the variable exon that encodes the ultralong CDR H3 of bovine antibodies.
Conserved amino acids seen in the mature antibodies are indicated beneath the schematic. (b) The
germline D8-2 gene segment encodes only four cysteines across its 148 bp sequence. However, the
high density of putative activation-induced cytosine deaminase (AID) hotspots, and the large fraction
of codons only a point mutation away from encoding cysteine, allow for the facile generation of
cysteine codons during somatic hypermutation. (c) AID mechanisms of mutation. Green nucleotides
indicate mutations; (i) deamination of cytosines to uracil can induce a mutation at C:G base pairs
during replication; (ii) during base excision repair (BER), uracil DNA glycosylase can remove the
uracil, creating an abasic site to induce mutation to any nucleotide following error-prone trans-lesion
synthesis; (iii) base pairs surrounding the initial lesion can also be mutated in a process dependent
upon mismatch repair (MMR); and (iv) large deletions and insertions occur in the bovine D8-2 exon.
These may be the result of errors during replication across the AID-induced lesions due to template
slippage or the error-prone end joining of AID-induced breaks (the latter outcomes are illustrated).
5. Uncovering the Structure of the Cow Ultralong CDR H3
The ultralong CDR H3 structure was first characterised in detail in two cryo-EM structures [18] and
has since been further analysed by Stanfield et al. [47], Dong et al. [46] and reviewed by others [19,48].
Briefly, the stalk of bovine long CDR H3 Abs consists of anti-parallel β- strands that protrude away
from the main Ab structure, akin to the strands that stabilize the anionic protrusions of some human
BNAbs. At the tip of this stalk is a disulphide-bonded knob domain that is likely the only region that
contacts the epitope. The removal of the knob domain completely abrogates Ab binding [18], while its
transplantation onto an antibody-scaffold is sufficient to transfer the donor Abs binding specificity
with only a moderate loss of neutralization potency [20].
The stabilisation of the ultralong cow CDR H3 does not require SHM, but instead the structure is
stabilized by residues encoded by the germline sequence of both the IgH and IgL chains [18,46,47].
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The 3′ end of VH1-7 contains a sequence duplication that encodes CTTVHQ, a relatively conserved
motif that stabilizes the base of the stalk by interacting with a DKAVG motif of CDR H1 [18,37,47].
All other CDRs, including those of the light chain, act to stabilise the CDR H3 domain but do not
participate directly in antigen binding. In fact, amino acid variability in CDR H1 and CDR H2 is
remarkably low [37]. The knob region itself lacks a hydrophobic core and is instead compacted and
shaped primarily by intra-domain disulphide bonding [18,19,47]. This feature explains the strong
preference for an even number of cysteine residues in mature sequences encoding ultralong CDR
H3s [18]. Nonetheless, of the four germline cysteines in the ultralong CDR H3, only the first is
apparently conserved and denotes the start of the CPDG motif at the start of the D segment [19].
Notably, there is a high density of consensus AID-targeting motifs within the germline D8-2 and the
majority of codons are only a single mutation away from encoding a cysteine [18,44]. NGS data have
further confirmed that somatic diversity is almost entirely focussed within the CDR H3 [18,44,47],
and massively alters the cysteine content and its distribution within the knob domain. This mediates
changes to the disulphide bonding pattern, the loop length and the overall architecture of the ultralong
CDR H3 to generate a diverse Ab repertoire from each VH1-7, DH8-2 and JH2-4 rearrangement. The 3′
of the D8-2 segment contains a fairly conserved pattern of alternating tyrosines that likely help to
support the knob domain [18].
Due to the relative infancy of the research, it is probable that diversity in the bovine ultralong CDR
H3 is even more expansive than that which has been characterised to date. Consistent with this, the
first five cryo-EM structures containing bovine ultralong CDR H3 regions suggested that the disulphide
bonds are restricted to cysteine residues within the globular mini-domain [18,47]. However, in seven
more recent structures, Dong et al. [46] identified a new disulphide bonding configuration in which
two cysteines in the stem form disulphides with two others in the knob domain. This linkage has the
effect of changing the angle of the antigen-binding site to generate further diversity [46]. Consistent
with this, the knob domain of the ultralong CDR H3 has an inherent flexibility, as demonstrated by the
difficulties in obtaining structures for many of the ultralong loops [46].
There is, however, remarkable conservation elsewhere in the Ab heterodimer. The sequences of
the light chain in bovine Abs is a relatively invariable version of IgλV30, so much so that this aspect
of the structure is generally indistinguishable from one Ab to another (Figure 3) [18,19,47]. In fact,
the Abs used in the biochemical and structural analysis by Wang et al. [18] were all purified with an
identical light chain, and two-thirds of CDR H3 sequences in a more recent study were successfully
expressed as a FAb with this same light chain [46]. This strongly suggests that light chain pairing is not
as strict as in human BNAbs, which will facilitate the creation of ultralong bovine CDR H3 libraries.
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Figure 3. Diversity in the ultralong cow antibodies is focused in the knob domain. The overlay of
the ribbon structures of two cow ultralong CDR H3 containing antibodies, BLV1H12 (heavy chain in
green, light chain in dark blue; PDB: 4K3D) and Bov-7 (heavy chain in cyan, light chain in red; PDB:
6E9U). There is a 96% amino acid homology between the bulk of the two heavy chains, such that these
regions of the overlaid structure have a root mean square error of 1.48 between equivalent α-carbons,
as calculated by TopMatch [49]. In contrast, the knob domains are so divergent (<30% amino acid
homology) that neither the amino acid sequences nor the 3D structures align successfully.
6. Long CDR H3 Structures Confer Broadly Neutralizing Anti-Viral Properties
A plethora of BNAbs have now been isolated and cloned from human HIV-1 patients that target
five sites on the surface protein, Env (Figure 4). The BNAbs with long CDR H3s typically target the
V1V2-apex epitope that is generated in the quaternary structure of Env (Figure 4a). The V1V2 apex of
Env is distal to the viral membrane and contains two relatively invariant features: The N-linked glycan
sites at residues 160, 156 and 173, and a highly conserved net positive charge [29]. The basic amino
acid side-chains in this region are thought to be critical for viral fitness as they facilitate conformational
changes associated with Env binding to CD4 [50]. PG9 and P16 are archetypal V1V2 apex-targeting
BNAbs, which potently neutralize cross-clade HIV-1 viruses in vitro via a wide, hammer-head-shaped
CDR H3 that possesses a negatively charged specificity loop at its apex. This forms salt bridges
with the positive loop at strand C of the V1V2 apex of Env and also contacts the surrounding
glycans (Figure 4b,c) [15,28,29]. The most potent anti-HIV-1 BNAbs identified to date are those of the
CAP256-VRC26 (CAP256) lineage, the members of which also target the positive region at the V1V2
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apex of Env via a long CDR H3 loop derived from a VDJ rearrangement encoding a 35 amino acid
CDR H3 [16]. Overall, 33 members of the CAP256 lineage have now been identified. However, in
significant contrast to the PG9-like Abs, the neutralizing activities of the most effective CAP256 BNAbs
are independent of the glycans surrounding the V1V2 site [16]. In these cases, the affinity maturation
of the long CDR H3s has conferred a remarkable sequence independence, allowing the BNAbs to
tolerate variability in their target. It appears that as long as the overall positive charge is maintained at
the V1V2 apex, mutations elsewhere in the epitope are not detrimental to BNAb potency. Together,
these Abs provide a proof of principle of the mechanisms by which extended CDR H3 structures
can nullify evasive viral features by reaching into conformationally restricted regions of the viral
glycoprotein [16,29]. These V1V2 directed BNAbs neutralize a large proportion of circulating HIV-1
strains and have the potential to be highly effective in protecting against HIV-1 transmission [51].
+ + + +- - - -
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 interface
Figure 4. Extended CDR H3 structures generate unusual antigen binding sites. (a) A cartoon showing
the five main epitopes on trimeric HIV-1 Env that are vulnerable to antibody-mediated neutralization.
Depicted are: the CD4 binding site (CD4bs; yellow), membrane-proximal external region (MPER;
green), the interface between gp120 and gp41 (pink), the V3 glycan supersite (orange) and the V1V2
apex (red), where the latter is the most distal from the viral surface. (b) A cartoon depicting the unusual
structure of the CDR H3 of PG9 in contact with its epitope. The long anionic loop generates extensive
electrostatic interactions with a conserved cationic region of HIV-1 Env. This interaction confers broad
neutralization as long as the charge is conserved. (c) Structures of two human anti-HIV-1 BNAbs, PG9
(PBD: 5VJ6) and CAP256.25 (PDB: 5DT1) show that their CDR H3s extend away from the main antibody
structure. The cow ultralong antibody BLV1H12 (PDB: 4K3D) is included for comparison, with the
stalk and knob regions highlighted.
It is probable that similarly extensive cohorts of these ‘super-antibodies’ can be recovered from
donors with previous exposure to other viruses [33]. For example, Ekiert et al. [30] used a phage-display
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library to isolate C05, a monoclonal BNAb capable of neutralizing diverse influenza A virus subtypes
that protected against lethal viral challenge in mice [30]. The binding of C05 is mediated by a
long 24 amino acid CDR H3 loop that inserts into the receptor binding site of the haemagglutinin
glycoprotein trimer to neutralize viruses from many subtypes of influenza A. This loop-insertion
mechanism generates exceedingly high-affinity contacts and is unlike any other previously documented
antibody interaction. The single loop generated by the long CDR H3 targets a small, conserved epitope
embedded in an otherwise hyper-mutable region [30,52].
More recently, the structure of a highly potent anti-Rabies virus BNAb bound to its epitope
was described [53]. Here, the broad activity was generated by the binding of the BNAb to a highly
conserved surface on the rabies virus glycoprotein G and locking G in its pre-fusion state. This means
that the glycoprotein cannot undergo the conformational changes that are associated with the release
of the viral genome into the cytoplasm upon exposure to the acidic pH of the endosome while the
BNAb is bound. Though the CDR lengths were normal, the antibody was highly resistant to the
mutagenesis of its epitope, with only mild losses in neutralization activity for single point mutations.
While the heavy chain contributed 80% of the paratope surface, the SHM of both the light and heavy
chains were found to be equally important for the breadth and potency of neutralization developed;
in fact, the most pronounced reductions in activity were observed with amino acid changes at the light
chain/heavy chain interface [53].
To date, the relationship between paratope and epitope has only been explored for one ultralong
CDR H3. Ultralong CDR H3 variable exons were amplified from the lymphocytes of cows immunised
with bovine viral diarrhoea virus (BVDV). These were then expressed and screened via ELISA and cell
surface binding for affinity for BVDV. This strategy isolated the BLV1H12 clone. Its cysteine-folded
knob structure is positively charged with multiple arginine residues and is entirely responsible for
antigen binding. Mutational scanning revealed that the C-terminal residues of the knob are the
most important for epitope binding, such that single arginine to alanine mutations here abolish the
interaction, whereas increasing the positive charge in this region by removing acidic residues reduced
specificity [18]. Further mutational analyses of the antigen binding sites of bovine ultralong CDR H3s
will shed light on the unique kinds of interactions these novel receptors can potentially generate.
It is now clear that Abs with unusual paratope structures have an enormous potential for
conferring broad protection, and the cow immune system may be a rich source of such candidate
BNAbs. Surprisingly, BNAbs are rapidly induced following the immunization of cattle with a stabilized
recombinant HIV-1 Env. Serum neutralisation breadth in the immunized cow was near total (96%)
vs. a panel of 117 pseudo-typed, cross-clade viruses. Importantly, this included 63 clade A, B and C
viruses that likely represent the most clinically relevant. This neutralizing activity could largely be
recapitulated by a single isolated monoclonal Ab, Nc-cow1; this BNAb had a mean IC50 of 0.03 µg/mL
and 72% coverage of the same 117 virus panel. Overall, this cow anti-HIV-1 antibody is amongst
the most potent of the BNAbs discovered to date [20,51]. Remarkably, moderate BNAb activity in
the serum was even observed after only six weeks [20]. This is considerably faster than the time
taken to generate equivalent Abs during the natural course of HIV-1 infection in people. The use
of a native-like recombinant Env trimer [54] likely contributed to the rapid induction observed in
cows, since immunization with less native-like HIV-1 Env proteins only induced Abs with moderate
potency. The use of the native-like immunogen in non-human primates (NHPs) has recently been
shown to induce potent neutralizing Abs that provide protection against simian/human HIV-1 (SHIV)
challenge [55] and the safety and utility of this immunogen is to be assessed in a Phase I clinical trial in
humans (Trial Identifier: NCT03699241). However, competitive binding assays demonstrated that the
monoclonal cow BNAbs targeted HIV-1 by engaging the CD4 binding site (CD4bs), which is a recessed,
heavily occluded but highly conserved epitope that the equivalent human long CDR H3 Abs do not
typically target. It is notable, however, that while BNAbs targeting the CD4bs are rare [51], this site
was also vulnerable to neutralization by camelid ‘nanobodies’ via their long CDR H3 [21].
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The most broad and potent of the camelid-derived heavy chain only nanobodies (VHH-A6)
neutralised 80% of a diverse mixture of 15 clade A, B and C pseudotyped viruses with a mean potency
of 2.6 µg/mL, but this could be significantly improved if two nanobodies were used in combination [21].
While, to the best of our knowledge, the specific neutralisation activity of the bovine ultralong CDR
H3 has not been assessed against viruses other than HIV, it is of interest that polyclonal preparations
of bovine immunoglobulins obtained from immunised cows can significantly reduce influenza A
viral titres in the nose and lung of influenza-infected mice and can completely prevent infection if
administered prophylactically. Future studies will help to elucidate the utility of this novel Ab type
against other viruses with significant disease burdens [56].
Nonetheless, it is remarkable that these unusual antigen binding domains can target this heavily
glycosylated receptor binding site of Env and exploit this distinct vulnerability in viral defences. These
encouraging studies suggest that, together with camelid ‘nanobodies’, the bovine Ab repertoire might
represent an untapped reservoir of potential BNAbs.
7. Summary and Future Directions
Broadly neutralizing antibodies with long CDR H3 are strong candidates for effective prophylaxis
and antibody-based immunotherapy [33,51]. Bovine antibodies with their ultralong CDR H3s hold
several notable advantages over other types of putative BNAb (Table 1) [19,20].
Table 1. Advantages and potential drawbacks of the ultralong CDR H3 structure.
Property Advantage Possible Drawbacks
Ultralong CDR H3 stalk and
knob structure
• Can reach conserved epitope
targets to confer potent
neutralization of broad viral
variants (20).
• Knob domain can be replaced by
bioactive peptides (59; 58)
• Novel antigen binding site
may generate anti-idiotype
antibodies when used
therapeutically in man.
Knob domain is highly stable
• Able to maintain specificity and
affinity after transplant onto
scaffolds (20).
• Strong binding even in typically
unfavourable conditions e.g.,
acidic pH (20).
• Unknown if neutralization is
also maintained at acidic pH.
IGHD8-2 gene encoding the
knob domain is primed
for diversification
• Expansive antibody repertoire
from only a single VDJ
rearrangement (18).
• It has not been shown how
rapidly the IGHD8-2 gene
can be mutated ex vivo to
generate insertions, deletions,
and cysteine codons.
All other CDRs are invariable
• Affinity maturation process
focussed solely on the CDR
H3 (19).
• Repertoire diversity relies on
extensive AID activity prior
to antigen exposure. If the
VDJ is knocked-in to a
different mammalian system,
diversity in the antigen naïve
repertoire may not
be sufficient.
Nonetheless, growing evidence suggests BNAbs can provide a protective passive immunity
that lasts for many weeks post-administration. Undoubtedly this could be improved by the rational
mutation of the constant domains [34]. The rapid ex vivo engineering of the antibody variable domain is
now also feasible. A recent study used a CRISPR-based mutagenesis strategy to generate a monoclonal
Ab with nanomolar affinity from an antigen naïve pool within only three rounds of selection [57]. It is
currently unknown if a similar strategy could generate effective antibodies from a library of bovine
Viruses 2020, 12, 473 12 of 15
antibodies bearing ultralong CDR H3s. However, any ex vivo diversification strategies can primarily
be focussed on the D segment, as most stabilizing structural features are already ‘hardcoded’ elsewhere
in the heavy chain and light chain sequences. Indeed, these variable domains can be transplanted onto
human Ab scaffolds whilst maintaining breadth and potency [20], which would circumvent any issues
with host-generated anti-cow antibodies. Therefore, these ultralong CDR H3 may be very amenable to
engineering for therapeutic purposes. Previous efforts to engineer the cow ultralong CDR H3 have
already shown that the knob structure can be replaced by bioactive peptides to target specific receptors,
including CXCR4 [58] or replaced with cytokines to generate highly functional fusion proteins [59].
The bovine antibody scaffold is thus also a versatile platform that has the potential to generate novel
therapeutics with enhanced kinetics, including longer plasma half-lives. To our knowledge, no studies
have yet asked whether bovine ultralong CDR H3 can be utilised in bi- or tri-specific antibodies.
However, the possibility of being able to use the same light chain for multiple ultralong CDR H3s
with different specificities may reduce issues with heavy chain/light chain pairing observed for some
multi-specific antibodies. Studies of the Ab repertoires of malaria-infected individuals demonstrated
that the entire extracellular domain of the LAIR1 receptor could be inserted at the CH1 hinge region.
Remarkably, together with somatic mutations, this generated an endogenous broadly reactive Ab with
two specific antigen binding domains on the same polypeptide chain [60]. Whether the ultralong cow
‘knob’ domains could be inserted at the CH1 region is yet to be explored.
Although anti-retroviral drug strategies have proven effective at lowering HIV-1 viraemia levels,
this suppression is dependent on a strict dosing regimen and significant issues still persist with global
drug availability. The targeted delivery of a prophylactic, BNAb-based intervention to vulnerable
populations could be an effective method for preventing HIV-1 infections, especially as some BNAbs
have been shown to confer protection that persists for months following treatment cessation [61].
A similar strategy can be exploited against other viruses, such as influenza or SARS-CoV-2 (Covid-19),
removing the need for costly annual vaccines or providing a therapeutic response to pandemic
outbreaks to stem community outbreaks. More speculatively, the application of a biological virucide
containing these stable BNAbs directly at sites permissive to HIV-1 entry could provide a convenient
method for limiting virus transmission. This is especially true since binding by ultralong CDR H3
BNAbs is maintained in acidic environments as low as pH 4 [20], as would be found on the vaginal
mucosal membranes that represent one of the primary sites for HIV-1 entry.
Finally, it is clear that these novel structures can be utilised to bind to unique epitopes inaccessible
to conventional antibodies. This understanding could expand antibody-based immunotherapies, as
well as generate a plethora of new experimental tools. There is also a vast potential for these novel
antibody types to target complex epitopes of therapeutic and biological interest.
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